1. Preclinical Safety Evaluation of Intranasally Delivered Human Mesenchymal Stem Cells in Juvenile Mice
- Author
-
Nuria Mellado-Damas, Laura Olmedo-Moreno, Alejandro Martin-Montalvo, Catalina Márquez-Vega, Yolanda Aguilera, Vivian Capilla-Gonzalez, Marina Benito, Hugo Guerrero-Cazares, Concepción Panadero-Morón, Víctor López, Junta de Andalucía, Instituto de Salud Carlos III, European Commission, Fundación Científica Asociación Española Contra el Cáncer, Asociación Pablo Ugarte, Fundación Española para la Ciencia y la Tecnología, [Aguilera,Y, Mellado-Damas,N, Olmedo-Moreno,L, López,V, Panadero-Morón,C, Martín-Montalvo,A, Capilla-González,V] Andalusian Molecular Biology and Regenerative Medicine Centre (CABIMER)-CSIC-US-UPO, Department of Regeneration and Cell Therapy, Seville, Spain. [Benito,M] Research Magnetic Resonance Unit, Hospital Nacional de Parapléjicos, Toledo, Spain. [Guerrero-Cázares,H] Department of Neurosurgery, Mayo Clinic, Jacksonville, USA. [Márquez-Vega,C] Pediatric Oncology Unit, Hospital Virgen del Rocio, Seville, Spain., This work was funded by grants from the Andalusian Regional Ministry of Health (PI 0272-2017 to V.C.-G), the Institute of Health Carlos III co-funded by Fondos FEDER (PI20/00341, CP19/00046 to V.C.-G, and PI18/01590, CPII19/00023 to A.M.-M.), the Fundación Científica de la Aso ciación Española Contra el Cáncer (IDEAS20051CAPI to V.C.-G.), the crowdfunding platform PRE CIPITA of the Spanish Foundation for Science and Technology (2018-000237 to V.C.-G.), and the Asociación Pablo Ugarte (+ VIDA project to V.C.-G).
- Subjects
0301 basic medicine ,Cancer Research ,Pathology ,medicine.medical_specialty ,Phenomena and Processes::Metabolic Phenomena::Pharmacokinetics::Tissue Distribution [Medical Subject Headings] ,Intranasal delivery ,Cell ,Células madre mesenquimatosas ,lcsh:RC254-282 ,Article ,Cell therapy ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Chemistry Techniques, Analytical::Spectrum Analysis::Magnetic Resonance Spectroscopy [Medical Subject Headings] ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,03 medical and health sciences ,0302 clinical medicine ,Contención de riesgos biológicos ,Tratamiento basado en trasplante de células y tejidos ,In vivo ,Anatomy::Fluids and Secretions::Body Fluids::Extracellular Fluid::Plasma [Medical Subject Headings] ,Organisms::Eukaryota::Animals [Medical Subject Headings] ,medicine ,Biosafety ,Technology and Food and Beverages::Technology, Industry, and Agriculture::Technology::Quality Control [Medical Subject Headings] ,Adverse effect ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Mice [Medical Subject Headings] ,business.industry ,Enfermedades del sistema nervioso ,Mesenchymal stem cell ,Nervous system disorders ,Diseases::Neoplasms [Medical Subject Headings] ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Clinical trial ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,Anatomy::Cells::Stem Cells [Medical Subject Headings] ,Diseases::Nervous System Diseases::Central Nervous System Diseases [Medical Subject Headings] ,Mesenchymal stem cells ,Nasal administration ,business ,030217 neurology & neurosurgery ,Ex vivo - Abstract
Mesenchymal stem cell (MSC)-based therapy is a promising therapeutic approach in the management of several pathologies, including central nervous system diseases. Previously, we demonstrated the therapeutic potential of human adipose-derived MSCs for neurological sequelae of oncological radiotherapy using the intranasal route as a non-invasive delivery method. However, a comprehensive investigation of the safety of intranasal MSC treatment should be performed before clinical applications. Here, we cultured human MSCs in compliance with quality control standards and administrated repeated doses of cells into the nostrils of juvenile immunodeficient mice, mimicking the design of a subsequent clinical trial. Short- and long-term effects of cell administration were evaluated by in vivo and ex vivo studies. No serious adverse events were reported on mouse welfare, behavioral performances, and blood plasma analysis. Magnetic resonance study and histological analysis did not reveal tumor formation or other abnormalities in the examined organs of mice receiving MSCs. Biodistribution study reveals a progressive disappearance of transplanted cells that was further supported by an absent expression of human GAPDH gene in the major organs of transplanted mice. Our data indicate that the intranasal application of MSCs is a safe, simple and non-invasive strategy and encourage its use in future clinical trials, This work was funded by grants from the Andalusian Regional Ministry of Health (PI- 0272-2017 to V.C.-G), the Institute of Health Carlos III co-funded by Fondos FEDER (PI20/00341, CP19/00046 to V.C.-G; PI18/01590, CPII19/00023 to A.M.-M.), the Fundación Científica de la Asociación Española Contra el Cáncer (IDEAS20051CAPI to V.C.-G.), the crowdfunding platform PRECIPITA of the Spanish Foundation for Science and Technology (2018-000237 to V.C.-G.), and the Asociación Pablo Ugarte (+ VIDA project to V.C.-G).
- Published
- 2021